Login To Trade  |  About IIFL
  • NIFTY  7950.9  2 0.03%
  • SENSEX 26220.95  66.12 0.25%
Divis Laboratories Ltd

BSE: 532488 | NSE: DIVISLAB ISIN: INE361B01024
Market Cap: [Rs.Cr.] 29,866.54 Face Value: [Rs.] 2
Industry: Pharmaceuticals - Indian - Bulk Drugs

Watchlist +
Director's Report
Directors' Report

Dear Shareholders,

Your Directors have pleasure in placing before you the Twenty Fourth Annual Report of the Company together with the Audited Accounts for the year ended 31st March 2014.


The Company’s financial performance, for the year ended 31st March, 2014 is summarized below:

(Rs. in lakhs)

Standalone Consolidated
Particulars 2013-14 2012-13 2013-14 2012-13
Net Sales 250718 212395 252535 213990
Other Operating Income 679 494 679 494
Other Income 8390 4851 7061 4481
Total Income 259787 217740 260275 218965
Expenditure 149511 130714 151765 132968
PBDIT 110276 87026 108510 85997
Depreciation 9206 7690 9212 7695
Finance Cost 206 178 206 178
Profit before tax (PBT) 100864 79158 99092 78124
Provision for tax:
Current Tax 20547 15300 20547 15300
MAT Credit (Entitlement)/ Utilisation (2367) 790 (2367) 790
Deferred Tax 3512 1926 3578 1833
Profit after tax (PAT) 79172 61142 77334 60201
Earnings per Share (EPS) (Rs.)
a) Basic 59.65 46.06 58.26 45.35
b) Diluted 59.65 46.06 58.26 45.35



Your company has achieved a sales growth of 18% for the year, on the back of a growth of 15% achieved during the last year. PBDIT increased by 27% at Rs. 110276 lakhs.

Profit after Tax for the year amounted to Rs.79172 lakhs, reflecting a growth of 29%. Earnings Per Share of Rs.2/-each works out to Rs. 59.65 for the year as against Rs. 46.06 last year.

Out of the total revenue, 44% came from North America, 37% from Europe, 6% from Asia, 9% from India and 4% from Rest of the World.

There has been a wide fluctuation in the exchange rates of currencies worldwide. Gain for the current and previous year is given below:

(Rs. in lakhs)

Particulars 2013-14 2012-13
Forex gain/(loss) 5041.79 1516.40

Provision has been made for Rs. 18180 lakhs towards Income-tax for the current year (net of MAT credit entitlement of Rs.2367 lakhs). Provision for last year amounted to Rs.16090 lakhs including a MAT credit utilization of Rs.790 lakhs. An amount of Rs. 3512 lakhs has been provided towards Deferred Tax Liability for the year as against Rs. 1926 lakhs during the previous year.


Our total income on consolidated basis increased to Rs. 252535 lakhs from Rs. 213990 lakhs in the previous year, recording a growth rate of 18%. PBDIT amounted to Rs. 108510 lakhs as against Rs. 85997 lakhs in the previous year. Profit after Tax for the year increased by 28% at Rs. 77334 lakhs as against Rs. 60201 lakhs in the previous year.


Your Directors are pleased to recommend a dividend of Rs.20 per equity share of Rs.2/- each, i.e., 1000% (last year Rs. 15 per equity share) for the financial year ended 31st March, 2014, subject to approval of members at the ensuing Annual General Meeting.

The total dividend payout for the current year amounts to Rs. 31059 lakhs (inclusive of tax of Rs.4512 lakhs) as against Rs. 23294 lakhs in the previous year. Dividend (including dividend tax) as a percentage of profits is 39% as compared to 38% in the previous year.

The dividend on equity shares, if declared at the AGM, will be paid to members whose names appear in the Register of Members as on 2nd August, 2014. In respect of shares held in dematerialised form, it will be paid to members whose names are furnished by Depositories as beneficial owners as on that date.


Our subsidiaries viz., M/s. Divis Laboratories (USA) Inc., in USA and M/s. Divi’s Laboratories Europe AG in Switzerland are engaged in marketing/distribution of nutraceutical products and to provide a greater reach to customers within these regions. During the year, the subsidiaries have achieved aggregate sales of Rs.12618 lakhs as against sales of Rs. 9078 lakhs previous year resulting in growth of 39% for the nutraceutical products in North America and Europe.

Brief operations of the subsidiaries are as under:

(Rs. in lakhs)

Particulars Divis Laboratories (USA) Inc., Divi's Laboratories Europe AG
Year ended 31-03-2014 31-03-2013 31-03-2014 31-03-2013
Sales 8764 6202 3854 2876
Other Income 0 0 1 1
Total Income 8764 6202 3855 2877
Materials Consumption 7182 5464 2399 1666
Operating Profit 1582 738 1456 1211
Salaries & Wages 528 518 176 134
Other Expenses 1232 707 2053 1169
Depreciation 4 4 1 1
Loss before tax 182 491 774 93
Tax Expense/(Asset) 66 (93) 0 0
Net Loss 248 398 774 93

Subsidiaries have achieved good growth in operating profit. Loss on forex currency translation for the year accounted to Rs.632 lakhs for US subsidiary and Rs.698 for Europe subsidiary.

Auditors of these subsidiaries have observed that the subsidiaries have suffered recurring losses, lack sufficient liquidity to continue operations and to continue as a going-concern depends on the temporary funding by the parent and successful realization of their business plans.

In accordance with the general circular issued by the Ministry of Corporate Affairs, Government of India, the Balance Sheet, Statement of Profit and Loss and other documents of the subsidiary companies are not being attached with the Balance Sheet of the Company. Shareholders who wish to have a copy of the full report and accounts of the subsidiaries will be provided the same on receipt of a written request from them. These documents will be available for inspection at the Registered Office of the Company and that of the respective subsidiary companies on any working day during business hours. The Consolidated Financial Statements presented by the Company include the financial results of its subsidiary companies.


Our Auditors have observed that the networth of the subsidiaries has eroded and consequent possibility of any temporary impairment of investment by way of equity in subsidiaries amounting to Rs.281.61 lakhs and non-recovery of loans of Rs.4796.31 lakhs given to the subsidiaries.

Over the last few years, we have made significant progress in terms of implementing the nutra facility and stabilising operations. Approvals have since been received from several major users and the outlook now looks very positive.

During the year, the subsidiaries have achieved good growth of business and have achieved operating profit. Net loss could have reduced significantly, but for the loss on account of foreign currency translation. With the significant efforts having been made towards optimizing operations and cost efficiency, the company is confident of achieving profitability at the subsidiaries and recovery of the loans given in the foreseeable future.


As stipulated in the listing agreement with the stock exchanges, the consolidated financial statements have been prepared by the Company in accordance with the relevant accounting standards under the Companies Act, 1956. The audited consolidated financial statements together with Auditors Report thereon form part of the Annual report.



Pursuant to the provisions of Section 161(1) of the Companies Act, 2013 and the Articles of Association of the Company, Mr. K.V.K. Seshavataram and Smt. S. Sridevi have been appointed as Additional Directors designated as Independent Directors w.e.f. 23rd June, 2014 and they shall hold office up to the date of the ensuing Annual General Meeting. The Company has received requisite notice in writing from a member proposing Mr. K.V.K. Seshavataram and Smt. S. Sridevi for appointment as Independent Directors.

Impending notification of Section 149 and other applicable provisions of the Companies Act, 2013, your Directors are seeking appointment of Dr. G. Suresh Kumar and Mr. R. Ranga Rao as Independent Directors for a term of five consecutive years upto 31st March, 2019. Details of the proposal for appointment of Mr. K. V. K. Seshavataram, Smt. S. Sridevi, Dr. G. Suresh Kumar and Mr. R. Ranga Rao are mentioned in the Explanatory Statement under Section 102 of the Companies Act, 2013 of the Notice of the Annual General Meeting.

The Company has received declarations from all the Independent Directors of the Company confirming that they meet with the criteria of independence as prescribed both under sub-section (6) of Section 149 of the Companies Act, 2013 and under Clause 49 of the Listing Agreement with the Stock Exchanges.


As per the provisions of the Companies Act, 2013 Mr. Kiran S. Divi will retire by rotation at the ensuing Annual General Meeting and, being eligible, offer himself for re-appointment.

The Board of Directors at its meeting held on June 23, 2014, subject to the approval of the shareholders, reappointed Dr. Murali K. Divi as the Chairman & Managing Director of the Company for a further period of five years from October 10, 2014 and Mr. N. V. Ramana as Executive Director of the company for a further period of five years from December 26, 2014.


Prof. C. Ayyanna has resigned as a Director of the company with effect from 20th May, 2013 due to personal reasons and other pre-occupations. The Directors place on record their appreciation for the contribution made by Prof. C. Ayyanna during his long tenure on the Board since 10.03.2001.

Dr. K. Satyanarayana, Independent Director has resigned from the Board with effect from 23rd June, 2014. Dr. K. Satyanarayana joined the Board on 08.08.1995 and has been part of Divis journey for 19 years. The Board would like to thank him for his long association with the company.

Mr. S. Vasudev, Independent Director has resigned from the Board with effect from 23rd June, 2014. Sri S. Vasudev has been part of the Board from 09.08.2004. The Board sincerely appreciates his contribution to the company during his tenure as member of the Board.


As required under Section 217 (2AA) of the Companies Act, 1956, Directors of your company hereby state and confirm that:

a) the applicable accounting standards have been followed in the preparation of the annual accounts;

b) the accounting policies selected were applied consistently and the judgements and estimates made are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2014 and its profit for the year ended on that date;

c) proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d) the annual accounts have been prepared on a going concern basis.


During the year, your directors have constituted the Corporate Social Responsibility Committee (CSR Committee). The said Committee has formulated and recommended to the Board, a Corporate Social Responsibility Policy (CSR Policy) indicating the activities to be undertaken by the Company, monitoring the implementation of the framework of the CSR Policy and recommending the amount to be spent on CSR activities.


The Auditors, M/s. P.V.R.K. Nageswara Rao & Co., Chartered Accountants, Hyderabad retire at the ensuing Annual General meeting and, being eligible, offer themselves for reappointment.

The Company has received letter from the auditors to the effect that their re-appointment, if made, would be within the prescribed limits under Section 141(3)(g) of the Companies Act, 2013 and that they are not disqualified for re-appointment.


Pursuant to Section 233B of the Companies Act, 1956, the Central Government has prescribed Cost Audit for the company. Based on recommendations of the audit committee and subject to approval of the Central Government, M/s. EVS & Associates, Cost Accountants, Hyderabad have been appointed as Cost Auditors for the year 2013-14.

The relevant cost audit report for the financial year 2012-13 has been filed within the due date on 3rd September, 2013. The due date for filing the report was 30th September, 2013.


A report on Management Discussion & Analysis for the year under review is provided in a separate section forming part of this Annual Report.


A report on Corporate Governance is included as a part of this Annual Report. Certificate from the Practicing Company Secretary Mr. V. Bhaskara Rao confirming the compliance with the conditions of Corporate Governance as stipulated under Clause 49 of the Listing Agreement is attached to this report.


Pursuant to the provisions of Section 205A(5) and 205C of the Companies Act, 1956, relevant amounts which remained unpaid or unclaimed for a period of seven years have been transferred by the Company, from to time to time on due dates, to the Investor Education and Protection Fund.

Pursuant to the provisions of Investor Education and Protection Fund (Uploading of information regarding unpaid and unclaimed amounts lying with companies) Rules, 2012, the Company has uploaded the details of unpaid and unclaimed amounts lying with the Company as on August 05, 2013 (date of last Annual General Meeting) on the websites of the Company and Ministry of Corporate Affairs.


As a matter of policy, your Company carries out transactions with related parties on an arms-length basis. Statement of these transactions is given in other explanatory information attached in compliance of Accounting Standard No.AS-18.


Your Directors wish to inform that the Company has not accepted any deposits from public covered by provisions of Section 58A of the Companies Act, 1956.


Particulars required under Section 217 (1) (e) of the Companies Act, 1956 read with Rule 2 of the Companies (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988 is given in the Annexure – I to this report.


Particulars of employees required to be furnished under Section 217 (2A) of the Companies Act, 1956 read with the Companies (Particulars of Employees) Rules, 1975 are given in the Annexure - II attached and forms part of this Report.


The Board expresses its gratefully appreciation for the continued assistance and co-operation received from Government authorities, Financial Institutions, Banks, customers, suppliers and investors. The Board also wishes to place on record its appreciation for the dedication and commitment extended by its employees at all levels and their contribution to the growth and progress of the company.

For and on behalf of the Board of Directors

Dr. Murali K. Divi

Chairman & Managing Director


23rd June 2014

Annexure - I

Information pursuant to Section 217(1)(e) of the Companies Act 1956 read with the Companies (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988.


Form for disclosure of particulars with respect to Conservation of Energy


Power and Fuel consumption

Particulars 2013-14 2012-13
1. Electricity
(a) Purchases:
Units 16,00,75,780 14,42,26,769
Total Amount - (Rs.lakhs) 10698 9526
Rate/Unit - Rs. 6.68 6.60
(b) Own generation:
Through diesel
Generator Units 15,75,897 51,11,404
Units per Lt. of diesel 3.36 3.41
Cost/Unit - Rs. 16.10 13.22
2. Coal (D/C grade)
Quantity (Kgs) 10,10,90,000 8,20,65,000
Total Cost - (Rs.lakhs) 3944 3068
Average rate - Rs. 3.90 3.74


Products Electricity (Units) Coal (D/C Grade) Others (Specify) } Since the Company manufac- tures different types of active pharmaceutical ingredients and intermediates, it is not practicable to give consump- tion per unit of production.


Form for disclosure of particulars with respect to technology absorption


1. Specific areas in which R&D is carried out by the Company. : Process development for Active Pharmaceutical Ingredients and inter- mediates.
2. Benefits derived as a resultof the above R&D : Developed new products and achieved cost and process efficiencies on existing products.
3. Future plan of action : To develop processes for newer products and intermediates.

4. Expenditure on R&D:

(Rs. in lakhs)

Particulars 2013-14 2012-13
a) Capital 965 423
b) Recurring 2539 2400
c) Total 3504 2823
d) Total R&D Expenditure as a percentage of Sales 1.40% 1.33%


1. Efforts in brief, made towards technology absorption and adoption. : The company has its own R&D Centre which develops technologies and processes for Active P h a r m a c e u t i c a l Ingredients and drug intermediates and these technologies are absorb- ed and implemented at the company’s Plants.
2. Benefits derived as a result of the above efforts : The company constantly has been executing process developments for its product range. Process optimization has been achieved in Produ- ction, which resulted in lower cost of production and substantial exports. The developments implemented brought more green chemistry by reducing reagents, minimize wastes and increasing recoveries.
3. Information regards import of technology during the last 5 years. : There is no import of technology.


Foreign Exchange earnings and outgo (on accrual basis)

(Rs. in lakhs)

Particulars 2013-14 2012-13
(a) Foreign Exchange earnings:
i) FOB Value of Exports 225764 186016
ii) Service charges 421 1877
(b) Foreign Exchange outgo:
i) Remittance in Foreign Currency:
Dividend (Net of Tax) 0.15 7
ii) CIF value of imports:
Raw Materials 48426 44799
Packing Materials 174 112
Lab Materials 52 203

(Rs. in lakhs)

Particulars 2013-14 2012-13
Capital Goods 1944 1624
Components & Spares 97 76
iii) Expenditure in Foreign Currency towards:
Memberships and Subscriptions 60 75
Books and Periodicals 14 10
Travelling Expenses 128 97
Consultancy Charges 288 264
Sales Commission 392 437
Foreign Bank Charges 53 49
Interest 0 0.10
Others 199 230


Information pursuant to Section 217 (2A) of the Companies Act, 1956 read with the Companies (Particulars of Employees) Rules, 1975

Name Age (Yrs) Qualifications Desig nation Date of commencement of employment Expe rience (Yrs) Gross remune ration (Rs.crores) Last employment
Dr. Murali K. Divi 63 M. Pharm. Ph. D. Chairman & Managing Director 12-Oct-90 39 33.39 Managing Director, Cheminor Drugs Ltd.
Ramana. N.V. 56 B.Sc.(Chem) Executive Director 26-Dec-
Futures & Options Quote
Expiry Date :
1,452.95    [25.65] ([1.73]%)
Instrument: FUTSTK
Expiry Date: 31-Jul-2014
Open Price: 1,475
Average Price: 1,452.39
No. of Contracts Traded: 867
Open Interest: 4,58,250
Underlying: DIVISLAB
Market Lot: 250
Previous Close: 1,452.95
Day's High | Low: 1,477 | 1,435.60
Turnover (Cr.): 31.48
Open Int. Change: 0,55,250 ([10.76]% )
Key Information

Key Executives:

Murali K Divi , Chairman & Managing Director

N V Ramana , Executive Director

Madhusudana Rao Divi , Director (Projects)

Kiran S Divi , President & Director

Company Head Office / Quarters:

7-1-77/E/1/303 Divi Towers,
Dharam Karan Road Ameerpet,
Andhra Pradesh-500016
Phone : Andhra Pradesh-91-40-23786300 / Andhra Pradesh-
Fax : Andhra Pradesh-91-40-23786460 / Andhra Pradesh-
E-mail : mail@divislaboratories.com
Web : http://www.divislaboratories.com


Karvy Computershare Pvt Ltd
Plot No 17-24 ,Vittal Rao Nagar ,Madhapur ,Hyderabad-500081

Fund Holding
Mon Tue Wed Thu Fri Sat Sun
22 23 24 25 26 27 28